Windtree Therapeutics, Inc. Weighted Average Shares Growth

Weighted Average Shares Growth of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Weighted Average Shares Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Weighted Average Shares Growth for the quarter ending June 29, 2020 was 40.64% (a 45.98% increase compared to previous quarter)
  • Year-over-year quarterly Weighted Average Shares Growth decreased by -94.61%
  • Annual Weighted Average Shares Growth for 2019 was 629.68% (a 86.79% increase from previous year)
  • Annual Weighted Average Shares Growth for 2018 was 337.1% (a 129.3% increase from previous year)
  • Annual Weighted Average Shares Growth for 2017 was 147.01% (a 655.06% increase from previous year)
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Weighted Average Shares Growth of Windtree Therapeutics, Inc.

Most recent Weighted Average Shares Growthof WINT including historical data for past 10 years.

Interactive Chart of Weighted Average Shares Growth of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Weighted Average Shares Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 40.64% 27.84%
2019 629.68% 754.05% 758.26% 896.1% 629.68%
2018 337.1% 416.95% 639.76% 617.07% 337.1%
2017 147.01% 74.57% 23.09% 9.89% 147.01%
2016 19.47% 10.65% 34.48% 33.95% 19.47%
2015 14.61% 24.06% 0.89% 1.09% 14.61%
2014 53.95% 55.52% 72.99% 94.22% 53.95%
2013 40.3% 26.11% 13.37% 60.68% 40.3%
2012 73.7% 80.14% 80.42% 49.54% 73.7%
2011 95.65% 86.36% 125.2% 98.17% 95.65%

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.